Aveo recently announced that the Tivozanib drug, in its second analysis, showed an improved survival hazard ratio. This penny stock news prompted the company’s stock to fly over 60% from Monday’s opening bell to Tuesday’s premarket high of $1.10. But just as quickly as it jumped, AVEO pulled back aggressively during the last 30 minutes of trading on September 10....
AVEO is a biotech with a successful PIII result already. Their PIII was short, 2 years, and the FDA didn't like it even though there was a major win on progression free survival. We get an update in August how the extended PIII is going. To my reasoning, there is > 50% chance this PIII corrects whatever happened last time which appears to have been the result of a...
Where are hedge fund managers pricing their fibonacci's?
Quick notes:
Fibonacci major resistance at 61.8% - good sign
RSI back to par
Stochastic crossover below lower threshold
MACD may swing back to crossover but need more information.
Resistance at 50d moving average
Using 1h chart because things are happening VERY QUICKLY on this stock.
Psychologically at...
Hello,
The chart here really says it all. Tomorrow or next day, AVEO will decide. You can expect a high swing day. Trade as you wish, these are the cues for a little bullish swing.
End a swing if it breaks below $1.80 (IMO). Good target would be $2.10 in the short term.
This is a classic example of Wall Street outlasting retail investors.
They want ALL of your shares and will take AVEO down to .50cents if necessary .
No basis for this at all. Good news doesn't matter.
Once they get almost all of the shares then the share price will go up.
Aveo just reported results on recent clinical trials, after a positive result the stock still plummeted 20%. With such a low market cap are we seeing manipulation or panic?
Either way we are left with nice looking setup; bullish divergence on the RSI. It has not turned yet but premarket the stock is up over 6% so it should turn immediately.
Time to find out....
Medical stock that's too thinly traded got mixed review on clinical trial results on Tivozanib, which showed efficacy, just not to level expected and testing new low for 2018 at 2.03 and below full fibonacci retracement of 2.10 as prior low. NASDAQ:AVEO
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
AVEO
